Long-term HIV dynamics subject to continuous therapy and structured treatment interruptions

Chemical Engineering Science

Volumn 64, Issue 7, 2009, Pages 1600-1617

  Hadjiandreou, Marios M ^a   Conejeros, Raul ^b   Wilson, D Ian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO   (Chile)

Author keywords

Chemotherapy; Drug resistance; Mathematical modelling; Optimal control

Indexed keywords

CHEMOTHERAPY; COMPUTER SIMULATION; DYNAMICS; OPTIMIZATION; SEMICONDUCTING SILICON; VIRUSES;

ANTIRETROVIRAL DRUGS; CLINICAL DATUM; DRUG EFFICACIES; DRUG RESISTANCE; DRUG-RESISTANT VIRUS; HIV DYNAMICS; IMMUNE RESPONSE; MATHEMATICAL MODELLING; NEW MODELS; OPTIMAL COMBINATIONS; OPTIMAL CONTROL; OPTIMAL TREATMENTS; OPTIMISATION; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE; SIDE-EFFECTS; SIMULATION RESULTS; STRUCTURED TREATMENT INTERRUPTIONS; T-CELLS; VIRUS STRAINS; WILD TYPES;

MATHEMATICAL MODELS;

EID: 60549086740     PISSN: 00092509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ces.2008.12.010     Document Type: Article

References (77)

1. Abbas U., and Mellors J. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. Proc. Natl. Acad. Sci. 99 (2002) 13377-13378
2. Adams B.M., Banks H.T., Kwon H., and Tran H.T. Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng. 1 (2004) 223-241
3. Adams B.M., Banks H.T., Davidian M., Kwon H., Tran H.T., Wynne S.N., and Rosenberg E.S. HIV dynamics: modeling, data analysis, and optimal treatment protocols. J. Comput. Appl. Math. 184 (2005) 10-49
4. Bajaria S.H., Webb G., and Kirschner D.E. Predicting differential responses to structured treatment interruptions during HAART. Bull. Math. Biol. 66 (2004) 1093-1118
5. Barreiro P., de Mendoza C., Gonzalez-Lahoz J., and Soriano V. Superiority of protease inhibitors over non-nucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy resumed after treatment interruption. Clin. Inf. Dis. 41 (2005) 897-900
6. Bonhoeffer S., May R.M., Shaw G.M., and Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. 94 (1997) 6971-6976
7. Braithwaite R.S., Justice A.C., Chang C.C., Fusco J.S., Raffanti S.R., Wong J.B., and Roberts M.S. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am. J. Med. 118 (2005) 890-898
8. Campello de Souza F.M. Modeling the dynamics of HIV-1 and CD4 and CD8 lymphocytes. IEEE Eng. Med. Biol. 18 (1999) 21-24
9. Celgene Corporation, 2008. Prescribing information. Available at 〈http://www.revlimid.com/pdf/REVLIMID_PI.pdf〉. Accessed January 2008.
10. Chun T.W., Davey R., and Engel D. Re-emergence of HIV after stopping therapy. Nature 401 (1999) 874-875
11. Clavel F., Race E., and Mammano F. HIV drug resistance and viral fitness. Adv. Pharmacol. 49 (2000) 41-66
12. Condra J.H., Holder D.J., Graham D.J., Shivaprakash M., Laird D.T., and Schleif W.A. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir. Antiviral Ther. 2 (1997) 31-32
13. DeJong M.D., Veenstra J., Stilianakis N.I., Schuurman R., Lange J.M.A., De Boer R.J., and Boucher C.A.B. Host-parasite dynamics and outgrowth of virus containing a single k70r amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc. Natl. Acad. Sci. 93 (1996) 5501-5506
14. DeRonde A., van Dooren M., van Der Hoek L., Bouwhuis D., de Rooij E., van Gemen B., De Boer R., and Goudsmit J. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75 (2001) 595-602
15. Deeks S.G., and Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS 16 Suppl 4 (2002) S157-S169
16. Deeks S.G., Grant R.M., Wrin T., Paxinos E.E., Liegler T., Hoh R., Martin J.N., and Petropoulos C.J. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17 (2003) 361-370
17. Devereux H.L., Youle M., Johnson M.A., and Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13 (1999) F123-F127
18. Ding A.A., and Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modelling HIV dynamics. Math. Biosci. 160 (1999) 63-82
19. Dorman K.S., Kaplan A.H., Lange K., and Sinsheimer J.S. Mutation takes no vacation: Can structured treatment interruptions increase the risk of drug-resistant HIV-1?. J. Acquir. Immune Defic. Syndr. 25 (2000) 398-402
20. Fang C.T., Hsu H.M., Twu S.J., Chen M.Y., Chang Y.Y., Hwang J.S., Wang J.D., and Chuang C.Y. Decreased HIV transmission after policy of providing free access to highly active therapy in Taiwan. J. Infect. Dis. 190 (2004) 879-885
21. Fauci A.S., Pantaleo G., Stanley S., and Weissman D. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124 (1996) 654-663
22. Ferguson N.M., deWolf F., Ghani A.C., Fraser C., Donnelly C.A., Reiss P., Lange J.M., Danner S.A., Garnett G.P., Goudsmit J., and Anderson R.M. Antigen-driven CD 4 + T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc. Natl. Acad. Sci. 96 (1999) 15167-15172
23. Filter R.A., Xia X., and Gray C.M. Dynamic HIV/AIDS parameter estimation with application to a vaccine readiness study in Southern Africa. IEEE Trans. Biomed. Eng. 52 (2005) 784-791
24. Furtado M., Callaway D., Phair J., Kunstman K.J., Stanton J.L., Macken C.A., Perelson A.S., and Wolinsky S.M. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340 (1999) 1614-1622
25. Garcia F., Plana M., Ortiz G., Bonhoeffer S., Soriano A., Vidal C., Cruceta A., Arnedo M., Gil C., Pantaleo G., Pumarola T., Gallart T., Nixon D.F., Miró J.M., and Gatell J.M. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15 (2001) F29-F40
26. Hadjiandreou M.M., Conejeros R., and Vassiliadis V.S. Towards a long-term model construction for the dynamic simulation of HIV infection. Math. Biosci. Eng. 4 (2007) 489-504
27. Hadjiandreou, M.M., Conejeros, R., Vassiliadis, V.S., Wilson, D.I., 2008. Long-term HIV dynamics: mathematical modelling and optimal control. In: Proceedings of the 2008 International Conference on Bioinformatics & Computational Biology, vol. 2, Las Vegas, USA, pp. 444-450.
28. Halfon P., Durant J., Clevenbergh P., Carsenti H., Celis L., Khiri H., De Smet K., De Brauwer A., Hulstaert F., and Dellamonica P. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS 17 (2003) 1351-1361
29. Huang Y., Rosenkranz S.L., and Wu H. Modelling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence, and phenotypic sensitivity. Math. Biosci. 184 (2003) 165-186
30. Igarashi T., Brown C.R., Endo Y., Buckler-White A., Plishka R., Bischofberger N., Hirsch V., and Martin M.A. Macrophages are the principal reservoir and sustain high virus loads in rhesus macaques following the depletion following the depletion of CD 4 + T-cells by a highly pathogenic SHIV: implications for HIV-1 infections of man. Proc. Natl. Acad. Sci. 98 (2001) 658-663
31. Joly M., and Pinto J.M. Role of mathematical modeling on the optimal control of HIV-1 pathogenesis. A.I.Ch.E. Journal 52 (2006) 856-885
32. Joshi H.R. Optimal control of an HIV immunology model. Optim. Control Appl. 23 (2002) 199-213
33. Khalili S., and Armaou A. Sensitivity analysis of HIV infection response to treatment via stochastic modeling. Chem. Eng. Sci. 63 (2008) 1330-1341
34. Khalili, S., Armaou, A., (2008b). An extracellular stochastic model of early HIV infection and the formulation of optimal treatment policy. Chem. Eng. Sci. 63, 4361-4372.
35. Kirschner D.E., and Perelson A.S. A model for the immune system response to HIV: AZT treatment studies. In: Arino O., Axelrod D., Kimmel M., and Langlais M. (Eds). Mathematical Population Dynamics: Analysis of Heterogeneity and Theory of Epidemics (1995), Wuerz Publishing, Winnipeg 295
36. Kirschner D.E., and Webb G.F. A mathematical model of combined drug therapy of HIV infection. J. Theor. Med. 1 (1997) 25-34
37. Krakovska O., and Wahl L.M. Costs versus benefits: best possible and best practical treatment regimens for HIV. J. Math. Biol. 54 (2007) 385-406
38. Krakovska O., and Wahl L.M. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting". Bull. Math. Biol. 69 (2007) 2627-2647
39. Krakovska O., and Wahl L.M. Optimal drug treatment regimens for HIV depend on adherence. J. Theor. Biol. 246 (2007) 499-509
40. Lawrence J., Mayers D.L., Hullsiek K.H., Collins G., Abrams D.I., Reisler R.B., Crane L.R., Schmetter B.S., Dionne T.J., Saldanha J.M., Jones M.C., and Baxter J.D. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 349 (2003) 837-846
41. Lisziewicz J., Rosenberg E., Lieberman J., Jessen H., Lopalco L., Siliciano R., Walker B., and Lori F. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340 (1999) 1683-1684
42. Margolick J.B., Donnenberg A.D., and Munoz A. T Lymphocytes homeostasis after seroconversion. J. Acquir. Immune. Defic. Syndr. 7 (1994) 415-416
43. Merck & Co., Inc., 2008. Capecitabine drug information, Available at 〈http://www.merck.com/mmpe/lexicomp/capecitabine.html〉. Accessed January 2008.
44. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., Larder B., Lutz T., Gute P., Weidmann E., Rabenau H., Phillips A., and Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14 (2000) 2857-2867
45. Morgan D., Mahe C., Mayanja B., Okongo J.M., Lubega R., and Whitworth J.A. HIV-1 infection in rural Africa: Is there a difference in median time to aids and survival compared with that in industrialized countries?. AIDS 16 (2002) 597-632
46. Nijhuis M., Deeks S., and Boucher C. Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 14 (2001) 23-28
47. Notermans D.W., Jurriaans S., deWolf F., Foudraine N.A., de Jong J.J., Cavert W., Schuwirth C.M., Kauffmann R.H., Meenhorst P.L., McDade H., Goodwin C., Leonard J.M., Goudsmit J., and Danner S.A. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 12 (1998) 167-173
48. Nowak M.A., Bonhoeffer S., Shaw G.M., and May R.M. Anti-viral drug treatment: dynamics in free virus and infected cell populations. J. Theor. Biol. 184 (1997) 203-217
49. Nowak M.A., and May R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology (2000), Oxford University Press, New York
50. Nowak, M.A., McMichael, A.J., 1995. How HIV defeats the immune system. Sci. Am. 58-65.
51. Pakker N.G., Kroon E.D., Roos M.T., Otto S.A., Hall D., Wit F.W., Hamann D., van der Ende M.E., Claessen F.A., Kauffmann R.H., Koopmans P.P., Kroon F.P., ten Napel C.H., Sprenger H.G., Weigel H.M., Montaner J.S., Lange J.M., Reiss P., Schellekens P.T., and Miedema F. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 13 (1999) 203-212
52. Paltiel A.D., Weinstein M.C., Kimmel A.D., Seage G.R., Losina III E., Zhang H., Freedberg K.A., and Walensky R.P. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N. Engl. J. Med. 352 (2005) 586-595
53. Panel on Antiretroviral Guidelines for Adult and Adolescents, 2006. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, Department of Health and Human Services, pp. 1-113. Available at 〈http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf〉. Accessed March 2007 (page 8, Table 5).
54. Pennisi E., and Cohen J. Eradicating HIV from a patient: Not just a dream?. Science 272 (1996) 1884
55. Phillips A.N., Dunn D., Sabin C., Pozniak A., Matthias R., Murdin-Geretti A.M., Clarke J., Churchill D., Williams I., Hill T., Green H., Porter K., Scullard G., Johnson A., Easterbrook P., Gilson R., Fisher M., Loveday C., Gazzard B., and Pillay D. Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. Antivir. Ther. 9 (2004) S151
56. Pomeranz R. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34 (2002) 91-97
57. Ribeiro R.M., Bonhoeffer S., and Nowak M.A. The frequency of resistant mutant virus before antiviral therapy. AIDS 12 (1998) 461-465
58. Rong L., Gilchrist M.A., Feng Z., and Perelson A.S. Modelling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility. J. Theor. Biol. 247 (2007) 804-818
59. Ruiz L., Ribera E., Bonjoch A., Romeu J., Martinez-Picado J., Paredes R., Díaz M., Marfil S., Negredo E., García-Prado J., Tural C., Sirera G., and Clotet B. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the retrogene study. J. Infect. Dis. 188 (2003) 977-985
60. Rusconi S., de Pasquale M.P., Milazzo L., Kurtagic S., Bulgheroni E., Citterio P., Galazzi M., La Seta Catamancio S., and Galli M. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antiviral Ther. 3 (1998) 203-207
61. Sabin C.A., Devereux H., Phillips A.N., Hill A., Janossy G., Lee C.A., and Loveday C. Course of viral load throughout HIV-1 infection. J. Acquir. Immune Defic. Syndr. 23 (2000) 172-177
62. Snedecor S.J. Comparison of three kinetic models of HIV-1 infection: implications for optimization of treatment. J. Theor. Biol. 221 (2003) 519-541
63. Stengel R.F. Mutation and control of the human immunodeficiency virus. Math. Biosci. 213 (2008) 93-102
64. Sterling T.R., Chaisson R.E., and Moore R.D. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 15 (2001) 2251-2257
65. - 3: disease progression, treatment durability, and drug toxicity. Clin. Infect. Dis. 36 (2003) 812-815
66. Stilianakis N.I., Boucher C.A.B., De Jong M.D., Van Leeuwen R., Schuurman R., and De Boer R.J. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J. Virol. 71 (1997) 161-168
67. Telenti A., and Rizzardi G. Limits to potent antiretroviral therapy. Rev. Med. Virol. 10 (2000) 385-393
68. UK Collaborative Group on HIV Drug Resistance, 2005a. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J. Infect. Dis. 192, 967-973.
69. UK Collaborative Group on HIV Drug Resistance, 2005b. Long-term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19, 487-494.
70. UK Group on Transmitted HIV Drug Resistance, 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. Br. Med. J. 331, 1368-1371.
71. Velasco-Hemandez J., Garcia J.A., and Kirschner D.E. Remarks on modeling host-viral dynamics and treatment. In: Chavez C., Blower S., Van Den Dreische P., Kirschner D., and Yakubu A.-A. (Eds). Mathematical Approaches for Emerging and Reemerging Infectious Diseases: An Introduction to Models, Methods and Theory vols. 1, 2 (2001), Springer, New York
72. Vergu E., Mallet A., and Golmard J. A modeling approach to the impact of HIV mutations on the immune system. Comput. Biol. Med. 35 (2005) 1-24
73. Walensky R.P., Goldie S.J., Sax P.E., Weinstein M.C., Paltiel A.D., Kimmel A.D., Seage G.R., Losina E., Zhang H., Islam R., and Freedberg K.A. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. JAIDS 31 (2002) 27-37
74. Weverling G.J., Lange J.M.A., Jurriaans S., Prins J.M., Lukashov V.V., Notermans D.W., Roos M., Schuitemaker H., Hoetelmans R.M., Danner S.A., Goudsmit J., and de Wolf F. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 12 (1998) F117-F122
75. Wilkes, G.M., Barton-Burke, M., 2006. Oncology Nursing Drug Handbook. Jones & Bartlett Publishers, pp. 480-481.
76. Yeni P.G., Hammer S.M., Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schechter M., Schooley R.T., Thompson M.A., Vella S., and Volberding P.A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. J. Am. Med. Assoc. 288 (2002) 222-235
77. Yerly S., Abdelrahim R., De Loes S.K., Hirschel B., Descamps D., Brun-Vézinet F., and Perrin L. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol. 72 (1998) 3520-3523